Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacticaseibacillus rhamnosus LR110
- Development stage
- Preclinical
- Lead developer
- Nordic Biotic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravaginal
01
Overview
Lacticaseibacillus rhamnosus LR110 (DSM 33794) is a gram-positive, probiotic bacterial strain isolated from human feces and is part of the NORDBIOTIC™ strain collection developed by Nordic Biotic. [1] The active ingredient is the live bacterial strain itself. This strain has been investigated in a clinical setting as part of a multi-strain probiotic formulation (NORDBIOTIC™) for the treatment of symptomatic acute respiratory tract infections, including COVID-19. Genomic analysis of the strain has identified genes associated with thiamine salvage, lactose metabolism, putrescine biosynthesis, and bacteriocin production, which suggest potential therapeutic applications in managing conditions such as inflammatory diseases, obesity, and allergies.
- Other names
- L. rhamnosus LR110Lactobacillus rhamnosus LR110
02
Targets
Shigella spp. (Shigella species)AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on Lacticaseibacillus rhamnosus LR110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lacticaseibacillus rhamnosus LR110.